Associated Papers
Influence of CYP2D6, CYP2C19, and CYP2C9 Pharmacogenetics and Clinical Factors on Dose-Normalized Venlafaxine/O-Desmethylvenlafaxine Metabolic Ratio in Spanish Patients.
Thomas L et al.
Pharmaceuticals (basel, Switzerland), 2026
Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.
Krebs K et al.
Npj Genomic Medicine, 2026
Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and Clinical Determinants of Fluoxetine-Norfluoxetine Pharmacokinetics in Real-World Clinical Conditions.
de la Cruz CG et al.
Pharmaceutics, 2025
From Genotype to Therapeutic Monitoring: Enhancing Tamoxifen Efficacy in Breast Cancer Treatment.
Mendes Batista AF et al.
Journal of Clinical Pharmacology, 2025
How CYP2D6 Polymorphism Modulates the Community-Wide Risk of Plasmodium vivax Infection: A Panel Study in Amazonian Brazil.
Puça MCSB et al.
The Journal of Infectious Diseases, 2025
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account.
Johansson I et al.
Clinical Pharmacology and Therapeutics, 2025
Impact of CYP2D6, MAOA, and UGT2B7 genetic variants on recurrence of Plasmodium Vivax in the Brazilian Amazon.
da Silva GS et al.
Scientific Reports, 2025
Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.
Litonius K et al.
Clinical Pharmacology and Therapeutics, 2025
Afro-Latin American Pharmacogenetics of CYP2D6, CYP2C9, and CYP2C19 in Dominicans: A Study from the RIBEF-CEIBA Consortium.
Guevara M et al.
Pharmaceutics, 2024
Molecular Mechanisms Underlying Single Nucleotide Polymorphism-Induced Reactivity Decrease in CYP2D6.
Becker D et al.
Journal of Chemical Information and Modeling, 2024
The variation landscape of CYP2D6 in a multi-ethnic Asian population.
Maulana Y et al.
Scientific Reports, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Risperidone plasma level, and its correlation with CYP2D6 gene polymorphism, clinical response and side effects in chronic schizophrenia patients.
Wang X et al.
Bmc Psychiatry, 2024
PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting.
Turner AJ et al.
Clinical Pharmacology and Therapeutics, 2023
Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations.
Twesigomwe D et al.
Clinical Pharmacology and Therapeutics, 2023
Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen.
Kanji CR et al.
Journal of Personalized Medicine, 2023
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M et al.
European Journal of Human Genetics : Ejhg, 2022
Transgenic HepaRG cells expressing CYP2D6 as an improved model of primary human hepatocytes.
Okuyama S et al.
Pharmacology Research & Perspectives, 2022
CYP2D6 gene resequencing in the Malagasy, a population at the crossroads between Asia and Africa: a pilot study.
Chan ER et al.
Pharmacogenomics, 2022
PacBio long-read amplicon sequencing enables scalable high-resolution population allele typing of the complex CYP2D6 locus.
Charnaud S et al.
Communications Biology, 2022
CYP2D6 genetic variation in Ugandans.
Miura J et al.
European Journal of Clinical Pharmacology, 2022
Prediction of the CYP2D6 enzymatic activity based on investigating of the CYP2D6 genotypes around the vivax malaria patients in Yunnan Province, China.
Dong Y et al.
Malaria Journal, 2021
Resolving discordant CYP2D6 genotyping results in Thai subjects: platform limitations and novel haplotypes.
Hongkaew Y et al.
Pharmacogenomics, 2021
Tri-Allelic Haplotypes Determine and Differentiate Functionally Normal Allele CYP2D6*2 and Impaired Allele CYP2D6*41.
Zanger UM et al.
Clinical Pharmacology and Therapeutics, 2021
Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data.
Chen X et al.
The Pharmacogenomics Journal, 2021
The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China.
Huang H et al.
Malaria Journal, 2021
Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.
Koopmans AB et al.
Translational Psychiatry, 2021
Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone.
Hongkaew Y et al.
Scientific Reports, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Genotype and Phenotype Concordance for Pharmacogenetic Tests Through Proficiency Survey Testing.
Moyer AM et al.
Archives of Pathology & Laboratory Medicine, 2020
An Explorative Study of CYP2D6's Polymorphism in a Sample of Chronic Pain Patients.
Fanelli A et al.
Pain Medicine (malden, Mass.), 2020
CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia.
Chamnanphon M et al.
Pharmacogenomics and Personalized Medicine, 2020
Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients.
Ximenez JPB et al.
Bmc Pharmacology & Toxicology, 2019
Resequencing CYP2D6 gene in Indian population: CYP2D6*41 identified as the major reduced function allele.
Manoharan A et al.
Pharmacogenomics, 2019
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Dynamic Effects of CYP2D6 Genetic Variants in a Set of Poor Metaboliser Patients with Infiltrating Ductal Cancer Under Treatment with Tamoxifen.
Ariza Márquez YV et al.
Scientific Reports, 2019
Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer.
Kasi PM et al.
Technology in Cancer Research & Treatment, 2019
Assessment of CYP2C9, CYP2C19, and CYP2D6 Polymorphisms in Allergic Patients with Chemical Sensitivity.
D'Attis S et al.
International Archives of Allergy and Immunology, 2019
Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions.
Storelli F et al.
Clinical Pharmacology and Therapeutics, 2018
Full-gene haplotypes refine CYP2D6 metabolizer phenotype inferences.
Wendt FR et al.
International Journal of Legal Medicine, 2018
Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.
Ahmad T et al.
Biochemical Pharmacology, 2018
Pharmacogenomics in Papua New Guineans: unique profiles and implications for enhancing drug efficacy while improving drug safety.
Tucci JD et al.
Pharmacogenetics and Genomics, 2018
Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.
Khan BA et al.
Clinical and Translational Science, 2018
Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes.
Numanagić I et al.
Nature Communications, 2018
P450 Pharmacogenetics in Indigenous North American Populations.
Henderson LM et al.
Journal of Personalized Medicine, 2018
CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study.
Brasil LW et al.
Malaria Journal, 2018